This week’s Immunology update highlights regulatory and clinical developments across autoimmune disease, oncology, and immune-cell programming platforms.
In Today’s Newsletter
Dive deeper
💻 Roche Liver Disease Panel launch [1] [27 May 2026]
https://www.roche.com/media/releases/med-cor-2026-05-27
Context: The panel includes LiverPRO, a CE-marked algorithm using age and routine blood markers to assess liver fibrosis risk.
Key point: Roche launched Liver Disease Panel, a suite of certified algorithms to support chronic liver disease management.
Implication: May expand screening, initiation, and follow-up at scale.
🧫 Imfinzi plus BCG FDA approval in NMIBC [2] [US • 28 May 2026]
https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-approved-in-us-for-early-bladder-cancer.html
Context: POTOMAC showed a 32% reduction in risk of high-risk recurrence, progression or death versus BCG alone.
Key point: FDA approved Imfinzi (durvalumab) plus BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer.
Implication: Introduces competition that may affect pricing and formulary access.
🧬 EMERALD-3 liver cancer PFS data [3] [01 Jun 2026]
https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-plus-imjudo-combined-with-lenvatinib-and-tace-reduced-the-risk-of-disease-progression-or-death-in-emerald-3-phase-iii-trial.html
Context: EMERALD-3 enrolled embolisation-eligible unresectable HCC patients; OS showed a positive trend.
Key point: Imfinzi plus Imjudo, lenvatinib and TACE reduced risk of progression or death by 30% versus TACE alone.
Implication: May influence prescriber choice and payer reviews pending full data.
🎯 BRAFTOVI BREAKWATER mCRC data [4] [US • 31 May 2026]
https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovi-regimen-nearly-doubles-median-progression
Context: BREAKWATER Cohort 3 showed median PFS of 15.2 months versus 8.3 months for comparator.
Key point: Pfizer reported that BRAFTOVI plus cetuximab and FOLFIRI nearly doubled median PFS in BRAF V600E-mutant mCRC.
Implication: May influence prescriber choice and payer reviews pending full data.
🦴 TREMFYA PsA label expansion [5] [US • 28 May 2026]
https://www.jnj.com/media-center/press-releases/fda-approves-label-expansion-cementing-tremfya-as-the-only-il-23-inhibitor-proven-to-help-stop-further-joint-damage
Context: The Phase 3b APEX study met ACR20 and structural damage endpoints versus placebo at 24 weeks.
Key point: FDA approved a TREMFYA label update for inhibition of structural joint damage in active psoriatic arthritis.
Implication: Introduces competition that may affect pricing and formulary access.
🩺 Oshi Health virtual GI study [6] [US • 01 Jun 2026]
https://www.prnewswire.com/news-releases/oshi-health-publishes-peer-reviewed-study-of-11-000-patients-validating-virtual-multidisciplinary-gi-care-at-scale-302785611.html
Context: Retrospective cohort included 11,345 patients across all 50 states and D.C. from Apr 2021 to Aug 2025.
Key point: Oshi Health published a peer-reviewed study reporting symptom improvement after virtual multidisciplinary GI care.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🌿 Soquelitinib Phase 1 AD signal [7] [US • 28 May 2026]
https://www.dermatologytimes.com/view/soquelitinib-demonstrates-efficacy-in-atopic-dermatitis-after-systemic-failure
Context: Phase 1 subgroup was small; three of four active-treated prior systemic failures responded.
Key point: Soquelitinib showed directional activity in moderate-to-severe atopic dermatitis after prior systemic therapy failure.
Implication: May influence prescriber choice and payer reviews pending full data.
☀️ CDA and Melanoma Canada screenings [8] [Canada • 27 May 2026]
https://www.globenewswire.com/news-release/2026/05/27/3301771/0/en/canadian-dermatology-association-in-partnership-with-melanoma-canada-offer-free-skin-cancer-screenings-on-parliament-hill.html
Context: The Mole Mobile was staffed by certified dermatologists and supported public education on sun safety.
Key point: Canadian Dermatology Association and Melanoma Canada offered free skin cancer screenings on Parliament Hill.
Implication: May expand screening, initiation, and follow-up at scale.
🧴 Zumilokibart Phase 2 APEX data [9] [US • 27 May 2026]
https://investors.apogeetherapeutics.com/news-releases/news-release-details/apogee-therapeutics-announces-positive-16-week-part-b-induction
Context: Mid-dose zumilokibart achieved 65.9% EASI-75 versus 23.4% placebo; Phase 3 is planned for 2H 2026.
Key point: Apogee reported positive 16-week Phase 2 APEX Part B induction results for zumilokibart in moderate-to-severe AD.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Regulatory activity is expanding earlier-line immunology and oncology labels, especially in NMIBC and PsA.
- Liver disease saw both diagnostic and therapeutic momentum, spanning Roche’s algorithm panel and AstraZeneca’s EMERALD-3 HCC data.
- Dermatology remains active across access, oral small molecules and long-acting biologics.
- Virtual specialty care evidence is moving from access claims toward large-scale real-world outcomes.
- Payers may face new evidence packages across oncology, immunology, GI and diagnostics.
🧰 See our full range of services. Discover how we can help you.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎯 Catch up on the Top Immunology news from the past two weeks, curated by the Lucidquest team.
FAQ
What did Roche launch for chronic liver disease?
Roche launched Liver Disease Panel, a certified algorithm suite for chronic liver disease management. It includes LiverPRO for fibrosis risk assessment using routine data. [1]
What changed for AstraZeneca’s Imfinzi in bladder cancer?
FDA approved Imfinzi plus BCG for adults with BCG-naïve, high-risk NMIBC. POTOMAC showed reduced risk of recurrence, progression or death versus BCG alone. [2]
What did EMERALD-3 show for unresectable HCC?
Imfinzi plus Imjudo, lenvatinib and TACE improved PFS versus TACE alone. OS had a positive trend, and follow-up continues. [3]
What is the Pfizer BRAFTOVI update in colorectal cancer?
BREAKWATER Cohort 3 showed improved PFS for BRAFTOVI plus cetuximab and FOLFIRI in BRAF V600E-mutant mCRC. OS benefit was also observed. [4]
What is new in the TREMFYA label?
FDA expanded the TREMFYA label to include inhibition of progression of structural joint damage in adults with active PsA. [5]
What did Apogee report for zumilokibart?
Apogee reported positive Phase 2 APEX Part B induction data in moderate-to-severe AD and plans Phase 3 trials in 2H 2026, pending regulatory interactions. [9]
Entities / Keywords
Roche, Liver Disease Panel, LiverPRO, chronic liver disease, CLD, liver fibrosis, Evido, CE-marked algorithm
AstraZeneca, Imfinzi, durvalumab, BCG, POTOMAC, NMIBC, bladder cancer
AstraZeneca, Imfinzi, Imjudo, tremelimumab, lenvatinib, TACE, STRIDE, EMERALD-3, HCC
Pfizer, BRAFTOVI, encorafenib, cetuximab, ERBITUX, FOLFIRI, BREAKWATER, BRAF V600E-mutant mCRC
Johnson & Johnson, TREMFYA, guselkumab, IL-23 inhibitor, psoriatic arthritis, PsA, APEX
Oshi Health, virtual GI care, multidisciplinary gastroenterology, JMIR, real-world evidence
Soquelitinib, atopic dermatitis, AD, systemic therapy failure, SID 2026
Canadian Dermatology Association, Melanoma Canada, Mole Mobile, Neutrogena, skin cancer screening
Apogee Therapeutics, zumilokibart, APG777, anti-IL-13, atopic dermatitis, EASI-75, EoE, asthma
